Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mining of natural diversity enables efficient and expressible peptide asparaginyl ligases.

Nature communications·2026
Same author

Correction to "Engineering Short Antimicrobial Peptides to Specifically Target <i>Fusobacterium nucleatum</i> in the Mixed Microbial Population".

ACS infectious diseases·2025
Same author

Initial cyclic-di-GMP upregulation triggers sporadic cellular expansion leading to improved cellular survival.

Biotechnology journal·2024
Same author

Targeted EpCAM-binding for the development of potent and effective anticancer proteins.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2023
Same author

On the design of a constitutively active peptide asparaginyl ligase for facile protein conjugation.

FEBS open bio·2023
Same author

Elucidation of Iron(III) Bioleaching Properties of Gram-Positive Bacteria.

ACS omega·2022
Same journal

Inhibition of Lin-11, Isl-1, and Mec‑3 Kinase (LIMK) Activity Attenuates Astrogliosis and Vascular Remodeling in an Experimental Model of Cuprizone-Induced Demyelination in Mice.

ACS pharmacology & translational science·2026
Same journal

Cyclin-Dependent Kinases 4 and 6 Inhibitors: An Emerging Therapeutic Framework from Growth Suppression to Tumor Clearance.

ACS pharmacology & translational science·2026
Same journal

Sertraline Enhances Bacterial Control without Adversely Affecting the Pharmacodynamic-Pharmacokinetic Properties of Frontline Tuberculosis Drugs.

ACS pharmacology & translational science·2026
Same journal

Repurposing FDA-Approved Drugs as Potential Inhibitors of Feline Infectious Peritonitis Virus 3CL<sup>pro</sup>: An Integrated In Silico and In Vitro Study with Synergistic Combination Analysis.

ACS pharmacology & translational science·2026
Same journal

Overcoming Pharmacokinetic and Peripheral Safety Challenges in Psychedelic Therapies: The Promise of Advanced Drug Delivery Systems.

ACS pharmacology & translational science·2026
Same journal

Head-to-Head Comparison of Monomeric, Homodimeric, and Heterodimeric Fibroblast Activation Protein-Targeting Radioligands Based on Small Molecule Inhibitor and Cyclic Peptide.

ACS pharmacology & translational science·2026
See all related articles

Related Experiment Video

Updated: Oct 16, 2025

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
06:28

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

Published on: October 1, 2015

13.6K

Engineering of Human Lactoferrin for Improved Anticancer Activity.

Yu Pan1, Niying Chua2, Kaisheng Lim1

  • 1Department of Biomedical Engineering, Southern University of Science and Technology (SUSTech), Shenzhen, China.

ACS Pharmacology & Translational Science
|October 18, 2021
PubMed
Summary
This summary is machine-generated.

Engineered lactoferrin fragments show potent anticancer activity. This novel recombinant human lactoferrin fragment (rtHLF4) is a promising, safer alternative to chemotherapy, with no observed hemolytic activity.

More Related Videos

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

6.0K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K

Related Experiment Videos

Last Updated: Oct 16, 2025

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
06:28

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

Published on: October 1, 2015

13.6K
Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

6.0K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Protease-digested lactoferrin fragments may possess enhanced therapeutic benefits.
  • Limited research exists on the anticancer properties of lactoferrin fragments.
  • Lactoferrin fragments offer a potential alternative to chemotherapy due to fewer side effects.

Purpose of the Study:

  • To isolate and characterize a recombinant engineered-lactoferrin fragment (rtHLF4).
  • To evaluate the anticancer activity and safety profile of rtHLF4.
  • To investigate the molecular mechanisms underlying rtHLF4's anticancer effects.

Main Methods:

  • Isolation and characterization of recombinant engineered-lactoferrin (rtHLF4).
  • Anticancer activity assays comparing rtHLF4 to full-length lactoferrin (flHLF).
  • Transcriptomic analysis of cancer biomarkers, including apoptosis, angiogenesis, and metastasis.
  • Hemolytic activity assays.

Main Results:

  • rtHLF4 demonstrated up to 100-fold greater anticancer activity than flHLF.
  • rtHLF4 exhibited anticancer effects in a shorter treatment duration.
  • Transcriptomic analysis revealed rtHLF4 upregulates pro-apoptotic markers and downregulates angiogenesis/metastasis proteins.
  • No hemolytic activity was observed for rtHLF4 at high concentrations.

Conclusions:

  • rtHLF4 is a potent anticancer agent with enhanced efficacy and safety.
  • rtHLF4 represents a promising candidate for further development as a novel cancer therapeutic.
  • The molecular mechanisms involve modulation of key cancer-related pathways.